2 Pages
English

Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent

Gain access to the library to view online
Learn more

Description

Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent PR Newswire LONDON, July 5, 2012 - New drug formulations and strong product pipelines expected to restore growth beyond 2013 LONDON, July 5, 2012 /PRNewswire/ -- Patent expiry of key blockbuster atypical antipsychotic drugs is likely to cause a decline in growth of the European bipolar disorder therapeutics market until 2013. However, approval of new drugs and improved depot formulations are expected to present growth opportunities from 2014 to 2018. New analysis from Frost & Sullivan (http://www.pharma.frost.com), Analysis of the European Bipolar-disorder Therapeutics Market, finds that the market earned revenues of $1.20 billion in 2011 and estimates this to reach approximately $1.22 billion in 2018, at a compound annual growth rate (CAGR) of 0.2 percent. Patent expiry of several key blockbuster atypical antipsychotics, including Seroquel from AstraZeneca, the only approved atypical antipsychotic for both bipolar mania and depression, is one of the key challenges for the market participants. "As generic equivalents of these blockbuster drugs reach the market, drug prices are expected to fall between 30-60 percent, causing an overall decrease of 10.1 percent in the European bipolar disorder therapeutics market until 2013," noted Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram.

Subjects

Informations

Published by
Reads 9
Language English

Exrait

Frost & Sullivan: European Bipolar
Therapeutics Market Slows Down in the Short
Term As Key Blockbuster Drugs Go Off Patent
PR Newswire
LONDON, July 5, 2012
- New drug formulations and strong product pipelines expected to
restore growth beyond 2013
LONDON
,
July 5, 2012
/PRNewswire/ -- Patent expiry of key blockbuster atypical
antipsychotic drugs is likely to cause a decline in growth of the European
bipolar disorder therapeutics market until 2013. However, approval of new
drugs and improved depot formulations are expected to present growth
opportunities from 2014 to 2018.
New analysis from Frost & Sullivan (http://www.pharma.frost.com),
Analysis of
the European Bipolar-disorder Therapeutics Market
, finds that the
market earned revenues of
$1.20 billion
in 2011 and estimates this to reach
approximately
$1.22 billion
in 2018, at a compound annual growth rate (CAGR)
of 0.2 percent.
Patent expiry of several key blockbuster atypical antipsychotics, including
Seroquel from AstraZeneca, the only approved atypical antipsychotic for both
bipolar mania and depression, is one of the key challenges for the market
participants.
"As generic equivalents of these blockbuster drugs reach the market, drug
prices are expected to fall between 30-60 percent, causing an overall decrease
of 10.1 percent in the European bipolar disorder therapeutics market until
2013," noted Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram.
Nonetheless, the high levels of unmet therapeutic needs present significant
market opportunities and business potential. Over three million people have
been diagnosed with some form (mania, hypomania or depression) of bipolar
disorder in
Europe
; this number is estimated to double by 2018. Most of the
currently approved drugs focus on the treatment of acute mania or hypomania,
which means that drugs targeting bipolar depression are the need of the hour.
"Any initiative to develop new and improved drug formulations – particularly
depot formulations of atypical antipsychotics that improves the efficacy, safety
and overall performance of the drug – will bear fruit in the coming years," said
Chidambaram. "Increasing investments in R&D and the commercialisation of
four potential product candidates within the next few years are expected to
confer bright growth prospects."
Strategic alliances and collaborations among large, specialty pharmaceutical
companies and technology providers will be the key tool for companies to
expand their global footprint and increase market shares.
Within the European Union,
Germany
is expected to remain the largest bipolar-
disorder therapeutics market while
Italy
and
Spain
grow at relatively fast rates.
If you are interested in more information on this study, please send an e-mail
with your contact details to Janique Morvan, Corporate Communications, at
janique.morvan@frost.com.
Analysis of the European Bipolar-disorder Therapeutics Market
is part